@UVic PhD, clinical researcher, heme/onc (myeloma) & palliative care NP, mama. Vanier scholar. Former President of @CANO_ACIO
#QualityOfLife#GlobalOncology
Pictures worth 1000 words - excellent 🇩🇰 #MMsm work in @AjHematology!
ABCD study of prophylactic toci and analysis of primary IVIG PPx with BCMA bsAbs in myeloma.
Answer clear as day: both PPx toci and PPx IVIG are essential safety interventions 💪🏻 We need to work on ⬇️ cost!
Hey everyone, want to catchup on the latest highlights from #ASCO26 ? I cover all plenary trials and other important studies.
My @ecancer highlights video is now up! Check it out.
https://t.co/PvTmTEG0Qv
The most important paper of #ASCO26 just dropped in Nature Med! Or any other @asco or @myESMO meetings to be honest. When you hear someone present “the toxicities were acceptable”, please respond “downplaying toxicities is not acceptable”. Thank you @NatureMedicine for publishing this piece.
https://t.co/ydAfoTWVJ0
Published today and presenting tomorrow! 📚➡️🎤
Excited to share our @ASCO Ed Book chapter on the contemporary challenges of EOC care @KimmieNgMD@drtarahenderson#IreneSu
Looking forward to tomorrow’s discussion at #ASCO26
https://t.co/geEMt1uKhR
@BradenMannsYYC Yes!! In addition to significant anxiety caused by abnormal results that ultimately may not change patient outcomes, such abnormal results may impede someone's ability to get life insurance, critical illness insurance, travel insurance, etc.
#Myeloma Paper of the Day: MajesTEC-9 trial of teclistamab vs. PVd or Kd after 1-3 prior lines shows tec w/ better 18-mo. PFS (69.8% vs. 26.9%), OS (79.2% vs. 68.6%) but more G3/4 AEs (CRS 66.0%, ICANS 4.1%, G3/4 infxns 41.6% vs 29%) & more deaths: https://t.co/iCI40IWYKa. #mmsm
Now that new results have started to trickle in from #ASCO26, I’d like to remind you all to use this primer to evaluate these results. My most downloaded paper from @JCOOP_ASCO .
https://t.co/wm7VADipUS
PATIENTS & CAREGIVERS — WE NEED YOU!
We’re aiming for 500 surveys to:
1️⃣ Review real patient data
2️⃣ Advocate for better diagnosis, treatment, and management of pancreatic cancer
Your voice matters.
Take the survey. Help us change the outcomes. https://t.co/TTqmRHk3gL
@panagis21@JHUPress Just ordered my copy (via https://t.co/V1Ve0USHa2)! I've been compiling a list of 'must reads' for the flight to/from Greece in July.
Can't wait to read it!
At diagnosis, investigation matters.
Exploring clinical trials early is critical—each standard treatment can limit future trial eligibility. Research shows clinical trial participants often have better outcomes and help advance new treatments.
Ask at diagnosis. Time matters.
Pleasure working with @ASCO on this! Living guidelines in myeloma #MMsm reflect how rapidly the field is changing... this update ≤6 months after our last one!
CAR-T and bsAbs (tec-dara) now on equal footing for relapsed myeloma at first relapse - shared decision-making is 🔑